Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Invitrogen™ Aflibercept Humanized Recombinant Human Monoclonal Antibody
Human Recombinant Monoclonal Antibody
Supplier: Invitrogen™ MA542317
This item is not returnable.
View return policy
Description
Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 °C for one week. Store at -20 to -80 °C for twelve months from the date of receipt.
Biosimilars targeting aflibercept biosimilars such as Yesafili, Opuviz, and Pavblu, function by inhibiting vascular endothelial growth factor (VEGF) pathways, crucial for angiogenesis and vascular permeability. These biosimilars emulate the activity of aflibercept, a recombinant fusion protein that combines portions of VEGF receptor 1 (VEGFR1) and VEGF receptor 2 (VEGFR2) with an immunoglobulin G (IgG) Fc fragment, effectively acting as a decoy receptor for VEGF-A, VEGF-B, and placental growth factor (PlGF). By binding to these growth factors, the biosimilars prevent their interaction with VEGF receptors on the surface of endothelial cells, thereby inhibiting the pathological angiogenesis and increased vascular permeability seen in conditions like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Clinical studies have shown that biosimilars such as SCD411, SB15, and QL1207 demonstrate comparable efficacy and safety to the reference product, aflibercept, in these indications, offering alternative treatment options that meet rigorous equivalency standards set by regulatory bodies.
Specifications
Aflibercept Humanized | |
Recombinant Monoclonal | |
Unconjugated | |
EYLEA; Zaltrap | |
Human VEGFA. | |
100 μg | |
Primary | |
-20°C, Avoid Freeze/Thaw Cycles | |
Liquid | |
Chemical |
ELISA | |
1.96 mg/mL | |
PBS with no preservative; pH 7.4 | |
Human | |
Protein A/G | |
RUO | |
Human | |
Antibody | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction